Spinifex Pharmaceuticals

About Spinifex Pharmaceuticals

Spinifex Pharmaceuticals was a clinical-stage pharmaceutical company established in 2005 as a spin-out from the University of Queensland. The company was founded upon the research of Professor Maree Smith and Dr. Bruce Wyse, who discovered a novel approach to treating chronic and neuropathic pain. Professor Smith, an internationally recognized researcher in the pain field with extensive expertise in biomedical discovery and drug development, identified that Angiotensin II Type 2 (AT2) receptor antagonists could be used as inhibitors for neuropathic pain. This foundational work led to the formation of Spinifex to commercialize the technology.

The company's core focus was the development of its lead product candidate, EMA401, a first-in-class oral treatment for chronic pain, particularly neuropathic pain, without the central nervous system side effects common in existing therapies. The business model centered on advancing EMA401 through clinical trials to demonstrate its safety and efficacy. The market for this drug is substantial, as neuropathic pain is a debilitating condition affecting a large percentage of the population, with many patients unresponsive to current treatments. EMA401 works by targeting AT2 receptors, which act outside the blood-brain barrier, thereby avoiding side effects like dizziness or confusion. The drug showed promise for treating pain associated with conditions like shingles (post-herpetic neuralgia), diabetes, and chemotherapy.

A significant milestone was the successful completion of a Phase 2 clinical trial, the positive results of which were published in The Lancet, demonstrating EMA401's effectiveness in reducing pain in patients with post-herpetic neuralgia. This achievement attracted substantial venture capital from firms including GBS Venture Partners, Brandon Capital Partners, and Uniseed. The company's progress culminated in its acquisition by Novartis in mid-2015 for an upfront payment of US$200 million, with the potential for over US$500 million in additional milestone payments. This event was considered one of the most successful venture capital exits in Australian history and allowed for the continued development of EMA401 within Novartis's pipeline.